Objective. To investigate the differences of candidate cerebrospinal fluid (CSF) biomarkers associated with multiple system atrophy (MSA) and Parkinson’s disease (PD). Method. Here, a systematic review and meta-analysis were conducted on studies related to CSF biomarkers associated with MSA and PD obtained from PubMed, Web of Science, Embase, and Cochrane databases. Data were pooled where appropriate and used to calculate standardized mean differences (SMDs) with 95% confidence intervals (CI). Heterogeneity was assessed using the statistic while Egger’s test was used to test for existing publication bias. Results. MSA patients had higher CSF t-tau (, 95% CI: 0.10 to 0.72) and YKL-40 (, 95% CI 0.12 to1.15) as well as DJ-1 (, 95% CI 0.67 to 1.42) levels than PD patients, while CSF p-tau (, 95% CI, -0.31 to -0.02) and Aβ-42 (, 95% CI, -0.55 to -0.12) levels in MSA patients were lower than those in PD patients. There were no differences in CSF’s GFAP and Flt3 ligand levels in both MSA and PD patients. Conclusion. The study revealed the differences in CSF biomarker levels between MSA and PD cohorts that can be further explored to clinically distinguish MSA from PD.

中文翻译：

---

与帕金森病相关的多系统萎缩中的脑脊液生物标志物：荟萃分析

目标。研究与多系统萎缩 (MSA) 和帕金森病 (PD) 相关的候选脑脊液 (CSF) 生物标志物的差异。方法。在这里，对从 PubMed、Web of Science、Embase 和 Cochrane 数据库中获得的与 MSA 和 PD 相关的 CSF 生物标志物相关的研究进行了系统评价和荟萃分析。在适当的情况下合并数据并用于计算具有 95% 置信区间 (CI) 的标准化平均差 (SMD)。使用统计量评估异质性，而使用Egger 检验来检验现有的发表偏倚。结果。MSA 患者的 CSF t-tau 较高（, 95% CI: 0.10 to 0.72) 和 YKL-40 (, 95% CI 0.12 to1.15) 以及 DJ-1 (, 95% CI 0.67 to 1.42) 水平高于 PD 患者，而 CSF p-tau (, 95% CI, -0.31 至 -0.02) 和 A β -42 (, 95% CI, -0.55 to -0.12) MSA 患者的水平低于 PD 患者。MSA 和 PD 患者的 CSF 的 GFAP 和 Flt3 配体水平没有差异。结论。该研究揭示了 MSA 和 PD 队列之间 CSF 生物标志物水平的差异，可以进一步探索这些差异以在临床上区分 MSA 和 PD。